EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial

Annie Xiao, Xiaochen Li, Chongkai Wang, Jian Ye, Marwan Fakih

European Journal of Cancer · 2024-12 · 213 · 115111

DOI: 10.1016/j.ejca.2024.115111 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2024-12. Verfasst von Annie Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: anxiao@coh.o…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Nivolumab, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Combination regorafenib, ipilimumab, and nivolumab (RIN) was evaluated in a phase 1 nonrandomized study (NCT04362839) of refractory microsatellite stable (MSS) metastatic colorectal cancer. Promising antitumor activity was previously reported in the non-liver metastatic (NLM) population. This updated analysis describes long-term survival outcomes in the NLM cohort and highlights durable remissions with potential cure following completion of RIN therapy. METHODS: Between May 2020 and January 2022, 39 patients with refractory MSS metastatic colorectal cancer were enrolled. Patients received RIN until progression, unacceptable toxicity, or completion at two years. The primary endpoint was recommended phase 2 dose (RP2D) selection. Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) at the RP2D level. RESULTS: 22 patients with refractory non-liver metastatic MSS colorectal cancer were treated at the RP2D of RIN. ORR was 36.4 % (8/22 patients), and median PFS was 5.0 months (95 % CI: 3-9). After a median follow-up of 42 months, the 1-, 2-, and 3-year PFS rates were 24.1 %, 24.1 %, and 19.3 % by RECIST. The median OS was 27.5 months (95 % CI: 14.0 to NE). At data cutoff, 6 patients had ongoing clinical benefit, including 3 responders who remain disease-free > 18 months after treatment completion. CONCLUSION: With extended follow-up, RIN combination therapy demonstrated durable clinical benefit in a subset of patients with NLM MSS metastatic colorectal cancer, including potential cure in 3 responders who remain disease-free > 18 months after treatment completion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNivolumabIpilimumabAntineoplastic Combined Chemotherapy ProtocolsPhenylurea CompoundsPyridinesHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overMicrosatellite Instability

Stichwörter der Autor:innen

ImmunotherapyIpilimumabMetastatic colorectal cancerMicrosatellite stableNivolumabRegorafenib

Substanzen

NivolumabregorafenibIpilimumabPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: anxiao@coh.org.
  • Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: xiaoli@coh.org.
  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: chowang@coh.org.
  • Department of Immuno-oncology, Beckman Research Institute of City of Hope, Duarte, CA, USA. Electronic address: jiye@coh.org.
  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: mfakih@coh.org.

Zitieren

APA

Xiao, A., Li, X., Wang, C., Ye, J., & Fakih, M. (2024). Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial. European Journal of Cancer, 213, 115111. https://doi.org/10.1016/j.ejca.2024.115111

Vancouver

Xiao A, Li X, Wang C, Ye J, Fakih M. Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial. European Journal of Cancer. 2024;213:115111. doi:10.1016/j.ejca.2024.115111

BibTeX
@article{Xiao2024,
  author = {Xiao, Annie and Li, Xiaochen and Wang, Chongkai and Ye, Jian and Fakih, Marwan},
  title = {Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {213},
  pages = {115111},
  doi = {10.1016/j.ejca.2024.115111}
}
Kostenlos starten →